Bussiness3 weeks ago
MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes
Completion of enrollment in the European Phase 3 clinical trial ARES designed to evaluate efficacy and safety of MaaT013 in the treatment of acute Graft-versus-Host Disease;...
